170277-31-3
170277-31-3
Chemical Structure
Infliximab
Synonym(s): Avakine; CT-P13; SB2; TA-650
- CAS No.: 170277-31-3
- Formula:N/A
- Molecular Weight:(145.98 kDa)
SMILES: [Infliximab]
Biological Activity:
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research[1][2].
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Infliximab | 99.28% | Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research. The component ratio of this product is Active ingredient : Excipients = 9 : 47. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716. [Content Brief]
- [2]. Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52. [Content Brief]
